NCT04909515 2022-09-01
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Y-mAbs Therapeutics
Phase 2 Withdrawn
Clinical Trials
6 trialsNCT00003405 2021-10-14
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Rush University Medical Center
Phase 2 Withdrawn
NCT01048086 2016-06-21
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
University of Iowa
Phase 2 Withdrawn
NCT01319838 2013-12-10
Aflac ST1001
Emory University
Phase 1 Withdrawn
NCT00003564 2012-02-22
Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas
M.D. Anderson Cancer Center
Phase 3 Withdrawn
NCT00003599 2012-02-22
Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer
M.D. Anderson Cancer Center
Phase 3 Withdrawn